The HIF target ATG9A is essential for epithelial barrier function and tight junction biogenesis.


Journal

Molecular biology of the cell
ISSN: 1939-4586
Titre abrégé: Mol Biol Cell
Pays: United States
ID NLM: 9201390

Informations de publication

Date de publication:
15 09 2020
Historique:
pubmed: 30 7 2020
medline: 23 6 2021
entrez: 30 7 2020
Statut: ppublish

Résumé

Intestinal epithelial cells (IECs) exist in a metabolic state of low oxygen tension termed "physiologic hypoxia." An important factor in maintaining intestinal homeostasis is the transcription factor hypoxia-inducible factor (HIF), which is stabilized under hypoxic conditions and mediates IEC homeostatic responses to low oxygen tension. To identify HIF transcriptional targets in IEC, chromatin immunoprecipitation (ChIP) was performed in Caco-2 IECs using HIF-1α- or HIF-2α-specific antibodies. ChIP-enriched DNA was hybridized to a custom promoter microarray (termed ChIP-chip). This unbiased approach identified autophagy as a major HIF-1-targeted pathway in IEC. Binding of HIF-1 to the ATG9A promoter, the only transmembrane component within the autophagy pathway, was particularly enriched by exposure of IEC to hypoxia. Validation of this ChIP-chip revealed prominent induction of ATG9A, and luciferase promoter assays identified a functional hypoxia response element upstream of the TSS. Hypoxia-mediated induction of ATG9A was lost in cells lacking HIF-1. Strikingly, we found that lentiviral-mediated knockdown (KD) of ATG9A in IECs prevents epithelial barrier formation by >95% and results in significant mislocalization of multiple tight junction (TJ) proteins. Extensions of these findings showed that ATG9A KD cells have intrinsic abnormalities in the actin cytoskeleton, including mislocalization of the TJ binding protein vasodilator-stimulated phosphoprotein. These results implicate ATG9A as essential for multiple steps of epithelial TJ biogenesis and actin cytoskeletal regulation. Our findings have novel applicability for disorders that involve a compromised epithelial barrier and suggest that targeting ATG9A may be a rational strategy for future therapeutic intervention.

Identifiants

pubmed: 32726170
doi: 10.1091/mbc.E20-05-0291
pmc: PMC7550696
doi:

Substances chimiques

ATG9A protein, human 0
Autophagy-Related Proteins 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
Membrane Proteins 0
Tight Junction Proteins 0
Transcription Factors 0
Vesicular Transport Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2249-2258

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK048520
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK050189
Pays : United States
Organisme : BLRD VA
ID : I01 BX002182
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK104713
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK103712
Pays : United States
Organisme : NIDDK NIH HHS
ID : R37 DK050189
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK095491
Pays : United States

Références

Annu Rev Physiol. 2016;78:301-25
pubmed: 26667076
J Cell Biochem. 2006 Dec 15;99(6):1616-27
pubmed: 16823775
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4586-91
pubmed: 10200306
Essays Biochem. 2012;53:41-54
pubmed: 22928507
Cell Host Microbe. 2015 May 13;17(5):662-71
pubmed: 25865369
Nat Cell Biol. 2012 Oct;14(10):1024-35
pubmed: 23023224
J Cell Biol. 2010 Apr 19;189(2):211-21
pubmed: 20404107
FASEB J. 2005 Jun;19(8):923-33
pubmed: 15923402
Mol Cell Biol. 2009 May;29(10):2570-81
pubmed: 19273585
Epithelial Cell Biol. 1995;4(1):25-34
pubmed: 8563793
Ann Am Thorac Soc. 2017 Sep;14(Supplement_3):S233-S236
pubmed: 28945477
Mol Biol Cell. 2015 Jun 15;26(12):2252-62
pubmed: 25904334
J Biol Chem. 2005 May 6;280(18):18283-90
pubmed: 15755735
Nature. 2001 May 31;411(6837):603-6
pubmed: 11385577
Cells. 2019 May 22;8(5):
pubmed: 31121959
J Biol Chem. 2008 Apr 18;283(16):10892-903
pubmed: 18281291
Mol Biol Cell. 2005 Oct;16(10):5040-52
pubmed: 16055505
Lancet. 2007 May 12;369(9573):1627-40
pubmed: 17499605
Br J Cancer. 2017 Sep 5;117(6):813-825
pubmed: 28797031
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):39-49
pubmed: 29018271
Nucleic Acids Res. 2020 Jan 8;48(D1):D87-D92
pubmed: 31701148
Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20842-6
pubmed: 19926846
Mol Cell. 2015 May 7;58(3):507-21
pubmed: 25891078
Gastroenterology. 2020 Sep;159(3):984-998.e1
pubmed: 32433978
Nat Cell Biol. 2012 Jan 22;14(2):177-85
pubmed: 22267086
Bioinformatics. 2005 Jul 1;21(13):2933-42
pubmed: 15860560
Mucosal Immunol. 2017 May;10(3):589-597
pubmed: 28327616
J Cell Sci. 2012 Mar 15;125(Pt 6):1488-99
pubmed: 22275429
Nature. 2001 May 31;411(6837):599-603
pubmed: 11385576
J Exp Med. 2001 May 7;193(9):1027-34
pubmed: 11342587
Microbes Infect. 2017 Mar;19(3):210-221
pubmed: 27664046
N Engl J Med. 2009 Nov 19;361(21):2066-78
pubmed: 19923578
Cancer Res. 2012 Apr 1;72(7):1773-83
pubmed: 22447568
Cell Metab. 2005 Jun;1(6):401-8
pubmed: 16054089
J Clin Invest. 2004 Oct;114(8):1098-106
pubmed: 15489957
Cell Death Differ. 2020 Mar;27(3):903-918
pubmed: 31988494
Nat Cell Biol. 2018 Sep;20(9):1013-1022
pubmed: 30154567
Ann N Y Acad Sci. 2017 Jun;1397(1):54-65
pubmed: 28415156
Am J Physiol Cell Physiol. 2019 May 1;316(5):C753-C765
pubmed: 30892937
Autophagy. 2014;10(12):2310-23
pubmed: 25551774
FASEB J. 2003 Mar;17(3):503-5
pubmed: 12514119
EMBO J. 2011 Feb 16;30(4):636-51
pubmed: 21169990
J Cell Biol. 1993 Feb;120(3):785-98
pubmed: 8093887
Cell Metab. 2011 May 4;13(5):495-504
pubmed: 21531332
Nat Rev Genet. 2009 Dec;10(12):821-32
pubmed: 19884889
Mol Cell Biol. 2003 Dec;23(24):9361-74
pubmed: 14645546
FASEB J. 2002 Apr;16(6):583-5
pubmed: 11919161
Mol Cell Biol. 2014 Dec;34(24):4379-88
pubmed: 25266655
J Biol Chem. 2018 Apr 20;293(16):6039-6051
pubmed: 29487135
Mol Biol Cell. 2005 Jun;16(6):2636-50
pubmed: 15800060
Cell Death Dis. 2016 Oct 27;7(10):e2434
pubmed: 27787518
Blood. 2011 Jun 9;117(23):e207-17
pubmed: 21447827
iScience. 2020 Jun 26;23(6):101226
pubmed: 32554188
Am J Physiol. 1994 Aug;267(2 Pt 1):C402-10
pubmed: 8074176
Mucosal Immunol. 2013 Nov;6(6):1110-8
pubmed: 23462909
Cell Death Differ. 2020 May;27(5):1677-1692
pubmed: 31740789
Gut. 2008 Sep;57(9):1294-6
pubmed: 18719139
J Clin Pathol. 2003 Mar;56(3):209-13
pubmed: 12610101
J Cell Sci. 2016 Oct 15;129(20):3781-3791
pubmed: 27587839
Nucleic Acids Res. 2019 Jan 8;47(D1):D419-D426
pubmed: 30407594
J Biol Chem. 2011 Feb 11;286(6):4718-26
pubmed: 21123177
J Biol Chem. 2015 Mar 13;290(11):7234-46
pubmed: 25616664
Microbes Infect. 2009 Oct;11(12):912-8
pubmed: 19573617
Am J Pathol. 2016 Apr;186(4):844-58
pubmed: 26878213
Nat Rev Immunol. 2017 Dec;17(12):774-785
pubmed: 28972206
BMC Genomics. 2009 Oct 27;10:497
pubmed: 19860899
J Exp Med. 2003 Oct 6;198(7):999-1010
pubmed: 14530374
Front Cell Dev Biol. 2018 Sep 10;6:104
pubmed: 30250843
J Crohns Colitis. 2014 Dec;8(12):1730-4
pubmed: 25240477
World J Gastroenterol. 2017 Mar 21;23(11):1944-1953
pubmed: 28373760
Histochem Cell Biol. 2017 Jul;148(1):85-93
pubmed: 28265783
Circ Res. 2019 Apr 26;124(9):1360-1371
pubmed: 30786833
Cell Death Dis. 2020 Feb 3;11(2):87
pubmed: 32015340
J Immunol. 2017 Oct 15;199(8):2976-2984
pubmed: 28893958
Am J Physiol Cell Physiol. 2002 Jun;282(6):C1235-45
pubmed: 11997237

Auteurs

Alexander S Dowdell (AS)

Mucosal Inflammation Program and Division of Gastroenterology and Hepatology, University of Colorado, Aurora, CO 80045.

Ian M Cartwright (IM)

Mucosal Inflammation Program and Division of Gastroenterology and Hepatology, University of Colorado, Aurora, CO 80045.

Matthew S Goldberg (MS)

Mucosal Inflammation Program and Division of Gastroenterology and Hepatology, University of Colorado, Aurora, CO 80045.

Rachael Kostelecky (R)

Mucosal Inflammation Program and Division of Gastroenterology and Hepatology, University of Colorado, Aurora, CO 80045.

Tyler Ross (T)

Mucosal Inflammation Program and Division of Gastroenterology and Hepatology, University of Colorado, Aurora, CO 80045.

Nichole Welch (N)

Mucosal Inflammation Program and Division of Gastroenterology and Hepatology, University of Colorado, Aurora, CO 80045.

Louis E Glover (LE)

Mucosal Inflammation Program and Division of Gastroenterology and Hepatology, University of Colorado, Aurora, CO 80045.
School of Biochemistry and Immunology, Trinity College Dublin, Ireland.

Sean P Colgan (SP)

Mucosal Inflammation Program and Division of Gastroenterology and Hepatology, University of Colorado, Aurora, CO 80045.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH